SCHEDULE: Invesco Ltd. Discloses 4.9% Stake in Charles River Labs

Invesco Ltd. has filed a Schedule 13G, reporting beneficial ownership of 4.9% of Charles River Laboratories International Inc. common stock as of March 31, 2026.

Summary

• Invesco Ltd. has reported beneficial ownership of 2,397,252 shares of Charles River Laboratories International Inc. common stock.
• This represents 4.9% of the class of securities.
• The filing is an amendment (Amendment No. 1) to a previous Schedule 13G.
• The reporting date for the event requiring this filing is March 31, 2026.
• Invesco Ltd. acts as a parent holding company for its investment advisers.
• The shares are held by clients of Invesco Ltd.'s investment advisers.
• No single individual has greater than 5% economic ownership of the shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of beneficial ownership by an institutional investor and does not contain performance data or strategic shifts that would inherently be positive or negative.

Positives

• Invesco Ltd. maintains a significant, though not controlling, stake in Charles River Laboratories.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control.

Risks

• As a significant shareholder, Invesco Ltd.'s investment decisions could influence market perception and stock price.
• The filing does not detail specific reasons for the investment or any strategic intentions beyond ordinary course of business.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance of Charles River Laboratories.

Management Comments

• "Invesco Ltd., in its capacity as a parent holding company to its investment advisers, may be deemed to beneficially own 2,397,252 shares of the Issuer which are held of record by clients of Invesco Ltd."
• "The shareholders of the Fund have the right to receive or the power to direct the receipt of dividends and proceeds from the sale of securities listed above."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like Invesco Ltd. when their beneficial ownership crosses a certain threshold. This filing indicates Invesco's ongoing investment activity in the life sciences sector, specifically within contract research organizations (CROs) like Charles River Laboratories, which are critical to pharmaceutical and biotech R&D.

Stakeholder Impact

• Shareholders: The filing may influence investor perception of institutional interest in Charles River Laboratories, potentially impacting trading activity.
• Management of Charles River Laboratories: Awareness of significant institutional holdings can inform strategic discussions and investor relations efforts.

Key Dates

Keywords

Schedule 13G, Invesco Ltd., Charles River Laboratories, beneficial ownership, common stock, investment, holding company, SEC filing